Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course radiotherapy followed by ivonescimab and CAPOX for locally advanced rectal cancer
ChiCTR2500100695Phase 2Recruiting
- Sponsor
- Union Hospital
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab, capecitabine and oxaliplatin in rectal adenocarcinoma, sponsored by Union Hospital. Primary endpoint: Complete response rate. Started Apr 2025; status: recruiting.
02
Drugs
ivonescimabcapecitabineoxaliplatin
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500100695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100695.